SIGA Technologies (SIGA) Names New CEO

October 13, 2016 8:34 AM EDT
Get Alerts SIGA Hot Sheet
Trade SIGA Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

SIGA Technologies, Inc. (SIGA) (OTC: SIGA) announced that Dr. Phil Gomez has been appointed the company’s new Chief Executive Officer. Current CEO Dr. Eric Rose will become Executive Chairman of the Board of Directors. Dr. Rose has been Chairman of the Board since 2007. Dr. Gomez brings decades of experience in drug development as well as deep management and business expertise. Most recently, Dr. Gomez served as a Principal at PricewaterhouseCoopers LLP in the Pharma & Life Sciences Management Consulting practice.

“I am so pleased to be joining SIGA at such an exciting time for the company. I look forward to working with Eric and the entire SIGA team to continue to grow our company and deliver our smallpox anti-viral treatment to our partners in government, as well as the public health and business communities,” said Dr. Gomez.

“I am proud to have led this extraordinary team who sets the standard for quality, innovation, and effectiveness in the field of smallpox anti-viral treatment. I look forward to continuing to work with SIGA’s world class executive team, scientists and staff to advance our trials, support our customers and grow our company,” said Dr. Rose.

At PwC, and at PRTM prior its acquisition by PwC, Dr. Gomez led the development and execution of business strategies for leading pharmaceutical companies. His practice focused on enhancing operating models for drug development, driving new corporate strategies with a focus on R&D operations and portfolio performance, and enabling clients to expand opportunities in the global vaccine market. In addition, Dr. Gomez has advised companies, governments, academic medical centers, and foundations in the fields of Biodefense and Global Public Health.

Prior to joining PwC and PRTM, Dr. Gomez worked at the National Institutes of Health in Bethesda, MD, where he established the Vaccine Production Program at the Vaccine Research Center in 2001. During his six-year tenure, his group manufactured more than forty bulk pharmaceutical compounds and more than fifteen candidate vaccines through innovative collaborations with industry to advance the development of vaccines against HIV, Ebola, West Nile Virus, Marburg, Severe Acute Respiratory System (SARS), and Influenza.

In 2007 Dr. Gomez earned the NIH Director's Award for the establishment of the vaccine pilot plant and for the rapid production of a candidate pandemic influenza vaccine. Prior to NIH, Dr. Gomez spent nearly a decade in the pharmaceutical industry at Abbott Laboratories, Sanofi Pasteur, and Baxter Healthcare leading process/product development organizations as well as project teams for product development.

Dr. Rose was elected Chairman of the Board of Directors on January 25, 2007, and, on March 1, 2007, became the company’s CEO. Dr. Rose has served as a director of SIGA since April 19, 2001 and served as Interim Chief Executive Officer of SIGA during April-June 2001. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2012, which he now serves as co-chair and professor. From 1994 through 2007, Dr. Rose served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. In addition to his roles at SIGA, Dr. Rose holds a position of Executive Vice President – Life Sciences at MacAndrews & Forbes Incorporated, a SIGA shareholder.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Management Changes, Management Comments

Related Entities

Definitive Agreement

Add Your Comment